TH metabolites (25), TRβ agonists (26), and liver-specific analogs (27) have been studied as potential therapeutics for treating both serum dyslipidemia and as potential therapies for NAFLD. Here, THRB is linked to metabolic dysfunction-associated steatotic liver disease.